TABLE 2.
Adverse events for osimertinib plus anlotinib in the treatment
| Adverse event | All grade | 1–2 grade | 3 grade | 4 grade | ||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | |
| Hand‐foot syndrome | 1.0 | 3.7 | 1.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hemoptysis | 2.0 | 7.4 | 2.0 | 7.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Epistaxis | 3.0 | 11.1 | 3.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hypertension | 5.0 | 18.6 | 4.0 | 14.9 | 0.0 | 3.7 | 0.0 | 0.0 |
| Weakness | 2.0 | 7.4 | 2.0 | 7.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Vomiting | 1.0 | 3.7 | 0.0 | 0.0 | 1.0 | 3.7 | 0.0 | 0.0 |
| Diarrhea | 5.0 | 18.6 | 5.0 | 18.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Proteinuria | 5.0 | 18.6 | 4.0 | 14.9 | 1.0 | 3.7 | 0.0 | 0.0 |
| Thrombocytopenia | 1.0 | 3.7 | 1.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Weight loss | 1.0 | 3.7 | 1.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Oral mucositis | 1.0 | 3.7 | 1.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |